PTE News and Press, PolarityTE Inc. From 03/12/20

PolarityTE, Inc. (PTE) Q4 2019 Results Earnings Conference Call March 12, 2020, 08:00 AM ET Company Participants Rich Haerle - Vice President of Investor Relations David Seaburg - President Paul Mann - Chief Financial Officer Richard Hague - Chief Operating Officer Nikolai So...

The following slide deck was published by PolarityTE, Inc. in conjunction with their 2019 Q4 earnings Read more ...

PolarityTE (NASDAQ: PTE ): Q4 net loss of 21.1M More news on: PolarityTE, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today reported results for calendar fourth quarter and year ended December 31, 2019. PolarityTE will host a conference call and webcast with Q&A today, T...

Gainers:  AIM ImmunoTech (NYSEMKT: AIM )  +44% . More news on: AIM ImmunoTech Inc., NeuroBo Pharmaceuticals, Inc., AquaBounty Technologies, Inc., Stocks on the move, , Read more ...

Thinly traded nano cap PolarityTE (NASDAQ: PTE ) slumps  46%  premarket on robust volume in reaction to its public offering of ~10.6M common shares and seven-year warrants to purchase up to the same number of shares at $2.80 at $2.35 per share and accompanying warrant. More new...

PolarityTE (NASDAQ: PTE ) has price d its public offering of ~10.6M common shares and warrants to purchase up to same number of common shares at a combined price of $2.35 per share and warrant, for a gross offering size of $25M. More news on: PolarityTE, Inc., Healthcare stocks news, Stoc...

Zosano Pharma (NASDAQ: ZSAN )  -47%  after pricing stock offering. More news on: Zosano Pharma Corporation, PolarityTE, Inc., PDS Biotechnology Corporation, Stocks on the move, , Read more ...

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced the pricing of an underwritten public offering of approximately 10,638,298 shares of its common stock and warrants to purchase up to 10,638...

PolarityTE, Inc. (Nasdaq: PTE) , a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock. ...